A study conducted last year indicates that economic incentives will encourage pregnant women to quit smoking. In response, the United Kingdom's National Health Service (NHS) has introduced guidelines estimating that for every 1000 pregnant women offered vouchers, 177 will quit smoking. "Evidence from the UK suggests that a plan offering vouchers worth up to approximately £400 over time (reducing with each relapse) is effective and cost-effective.
The guidelines emphasize that women should undergo a biochemical test to prove they have quit smoking before receiving cash coupons. Additionally, it adds that healthcare professionals should provide clear and up-to-date information about e-cigarettes to anyone interested in using them to quit smoking, while also mentioning that their long-term health effects remain uncertain.
Trial project begins.
A new pilot program has recently been launched in the northwest of England. East Cheshire, which is currently participating in the program, has a smoking rate higher than the national average, with 10% of pregnant residents continuing to smoke.
Dr. Matt Tyrer, the Public Health Director of Dongchai County Council, told Filter that while the figure may sound significant, it could potentially save up to £450,000 in healthcare costs. The UK government explains that aside from the personnel cost, smoking causes a loss of £14.7 billion to the economy each year, with £2.5 billion belonging to the National Health Service.
The proposal to offer economic incentives was initially put forward by the Royal College of Physicians (RCP), which emphasized that smokers should be offered "choice to quit smoking services" at any point of contact with the NHS. The group emphasized that since most smokers typically come from "lower socio-economic groups," pregnant women should be given financial incentives to encourage them to achieve their goals.
UK's smoke-free 2030
These recommendations were put forward as part of a report compiled by the RCP, aimed at addressing what measures can be taken to achieve the government's "smoke-free 2030" goal. Sadly, recent data suggests that the current target won't be truly achievable until 2050.
The ability of the United Kingdom and other countries to address major public health challenges is unquestionable. The Covid-19 pandemic has posed the largest new challenge to global and UK health in decades, attracting unprecedented public health and economic responses. However, in 2020, while Covid-19 killed approximately 80,000 British citizens, smoking caused the deaths of 94,000 people, according to the report.
Statement:
This article is compiled from third-party information and is only intended for communication and learning within the industry.
This article does not represent the viewpoint of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the content. The translation of this article is only intended for industry exchange and research.
Due to limitations in translation ability, the compiled article may not express the same meaning as the original. Please refer to the original text for accuracy.
2FIRSTS aligns completely with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, and foreign-related expressions and positions.
The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
